Yuen T So, MD
Neurology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. So’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G53824 · Current
Licensed to practise in California · since 1984 · expires 2028-08-31 · Yale University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$12,973
Medicare paid this office $12,973 for 93 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 40 | $5,061 | $112 |
| Nerve test | 11 | $1,201 | $109 |
| Muscle electrical test | 26 | $1,070 | $37 |
| Nerve test | 12 | $868 | $72 |
| Muscle electrical test | 24 | $524 | $16 |
Who their Medicare patients are
93 Original Medicare patients in 2024. Average age 72 · Under 65 14% · 85 and older 12% · Women 52% · Also on Medicaid 22% · Health risk score 1.98. Above the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 69% · Coronary heart disease 33% · Depression 29% · Chronic kidney disease 25% · Diabetes 23% · Atrial fibrillation 23% · Heart failure 20% · Cancer 20% · COPD 18%.
The office billed $381,235, Medicare allowed $18,064 and paid $12,973; for 173 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 93 | 173 | 72 | 1.98 | $381,235 | $12,973 |
| 2023 | 147 | 317 | 72 | 1.38 | $563,932 | $24,332 |
| 2022 | 213 | 508 | 71 | 1.59 | $743,158 | $40,591 |
| 2021 | 182 | 397 | 73 | 1.45 | $584,885 | $32,511 |
| 2020 | 194 | 440 | 72 | 1.66 | $583,546 | $32,881 |
| 2019 | 210 | 480 | 70 | 1.44 | $648,086 | $36,046 |
| 2018 | 234 | 516 | 71 | 1.45 | $715,167 | $39,662 |
| 2017 | 224 | 510 | 71 | 1.33 | $717,473 | $36,552 |
| 2016 | 242 | 524 | 70 | 1.40 | $672,220 | $42,656 |
| 2015 | 277 | 563 | 69 | 1.60 | $637,000 | $47,825 |
| 2014 | 274 | 635 | 70 | 1.40 | $433,155 | $48,599 |
| 2013 | 266 | 555 | 70 | 1.56 | $238,389 | $40,056 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Long return visit (40+ min) | 63 | $11,538 | $125 |
| Muscle electrical test | 45 | $2,157 | $41 |
| Nerve test | 18 | $2,089 | $116 |
| Nerve test | 26 | $1,727 | $66 |
| Nerve test | 16 | $1,478 | $92 |
| Muscle electrical test | 41 | $990 | $16 |
2022: 9 services
| Long return visit (40+ min) | 72 | $12,024 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $4,314 | $92 |
| Nerve test | 31 | $3,763 | $121 |
| Nerve test | 33 | $3,142 | $95 |
| Muscle electrical test | 58 | $3,016 | $42 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,909 | $174 |
| Muscle electrical test | 57 | $1,391 | $17 |
| Return visit (30+ min) | 17 | $1,300 | $62 |
| Nerve test | 16 | $1,166 | $73 |
2021: 8 services
| Long return visit (40+ min) | 62 | $10,950 | $124 |
| Return visit (30+ min) | 30 | $3,003 | $77 |
| Nerve test | 23 | $2,833 | $123 |
| Nerve test | 27 | $2,567 | $95 |
| New patient visit (60+ min) | 13 | $1,985 | $153 |
| Muscle electrical test | 44 | $1,885 | $39 |
| Muscle electrical test | 52 | $1,258 | $17 |
| Nerve test | 19 | $1,226 | $65 |
2020: 9 services
| Long return visit (40+ min) | 51 | $6,849 | $98 |
| Nerve test | 28 | $2,815 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,735 | $195 |
| Muscle electrical test | 53 | $2,507 | $42 |
| Return visit (30+ min) | 33 | $2,383 | $60 |
| Nerve test | 17 | $2,068 | $122 |
| Nerve test | 27 | $2,025 | $75 |
| New patient visit (60+ min) | 13 | $1,713 | $132 |
| Muscle electrical test | 43 | $1,226 | $18 |
2019: 10 services
| Long return visit (40+ min) | 71 | $10,241 | $95 |
| New patient visit (60+ min) | 34 | $4,993 | $147 |
| Return visit (30+ min) | 40 | $3,044 | $62 |
| Muscle electrical test | 58 | $2,956 | $42 |
| Nerve test | 24 | $2,848 | $119 |
| Nerve test | 24 | $2,421 | $101 |
| Nerve test | 16 | $2,393 | $150 |
| Muscle electrical test | 54 | $1,357 | $17 |
| Nerve test | 17 | $1,287 | $76 |
| Muscle electrical test | 11 | $388 | $35 |
2018: 12 services
| Long return visit (40+ min) | 66 | $8,155 | $94 |
| New patient visit (60+ min) | 32 | $4,494 | $140 |
| Long return visit (40+ min) | 32 | $3,192 | $100 |
| Nerve test | 25 | $3,033 | $121 |
| Nerve test | 15 | $2,203 | $147 |
| Muscle electrical test | 45 | $2,053 | $41 |
| Nerve test | 20 | $1,875 | $94 |
| Return visit (30+ min) | 29 | $1,777 | $56 |
| Muscle electrical test | 43 | $923 | $15 |
| Muscle electrical test | 14 | $701 | $41 |
| Muscle electrical test | 17 | $435 | $17 |
| Muscle electrical test | 12 | $386 | $32 |
2017: 9 services
| Long return visit (40+ min) | 85 | $11,142 | $90 |
| New patient visit (60+ min) | 46 | $6,318 | $137 |
| Muscle electrical test | 72 | $3,843 | $42 |
| Nerve test | 28 | $2,746 | $98 |
| Nerve test | 21 | $2,587 | $123 |
| Nerve test | 15 | $2,187 | $146 |
| Nerve test | 26 | $1,934 | $74 |
| Muscle electrical test | 51 | $1,356 | $17 |
| Return visit (30+ min) | 19 | $1,274 | $55 |
2016: 9 services
| Long return visit (40+ min) | 101 | $14,487 | $96 |
| New patient visit (60+ min) | 66 | $9,827 | $149 |
| Muscle electrical test | 65 | $3,508 | $42 |
| Nerve test | 25 | $2,972 | $119 |
| Nerve test | 18 | $1,767 | $98 |
| Nerve test | 22 | $1,617 | $73 |
| New patient visit (45+ min) | 13 | $1,479 | $114 |
| Return visit (30+ min) | 22 | $1,431 | $65 |
| Muscle electrical test | 44 | $982 | $17 |
2015: 12 services
| Long return visit (40+ min) | 105 | $14,721 | $93 |
| New patient visit (60+ min) | 69 | $10,212 | $148 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,617 | $181 |
| Muscle electrical test | 65 | $3,171 | $41 |
| Nerve test | 31 | $2,842 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $2,049 | $93 |
| Nerve test | 13 | $1,889 | $145 |
| Nerve test | 15 | $1,841 | $123 |
| Nerve test | 24 | $1,773 | $74 |
| Return visit (30+ min) | 20 | $1,473 | $67 |
| Muscle electrical test | 43 | $1,104 | $17 |
| Nerve test | 12 | $681 | $57 |
2014: 9 services
| Long return visit (40+ min) | 115 | $16,872 | $91 |
| New patient visit (60+ min) | 62 | $8,748 | $141 |
| Nerve test | 35 | $3,383 | $97 |
| Muscle electrical test | 63 | $3,306 | $42 |
| Nerve test | 20 | $2,306 | $115 |
| Nerve test | 26 | $1,999 | $71 |
| Return visit (30+ min) | 19 | $1,379 | $66 |
| Muscle electrical test | 55 | $1,367 | $17 |
| Nerve test | 12 | $725 | $60 |
2013: 9 services
| Long return visit (40+ min) | 111 | $14,483 | $87 |
| New patient visit (60+ min) | 47 | $6,831 | $145 |
| Return visit (30+ min) | 37 | $2,723 | $65 |
| Nerve test | 26 | $2,295 | $88 |
| Muscle electrical test | 52 | $2,171 | $33 |
| Nerve test | 30 | $2,112 | $70 |
| New patient visit (45+ min) | 16 | $1,647 | $103 |
| Muscle electrical test | 39 | $1,050 | $17 |
| Nerve test | 11 | $645 | $59 |
Drugs they prescribed that Part D paid
$959,813
Pharmacies billed $959,813 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 111) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
70 generic and 41 brand-name prescriptions · $959,813 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Radicava Ors | 22 | $307,410 | $13,973 |
| Riluzole | 15 | $990 | $66 |
| Mycophenolate Mofetil | 20 | $961 | $48 |
Year by year
| 2024 | 111 | 29 | 0% (0) | 37% | $959,813 |
| 2023 | 271 | 50 | 0% (0) | 30% | $1,466,041 |
| 2022 | 266 | 48 | 0% (0) | 21% | $1,238,368 |
| 2021 | 167 | 28 | 0% (0) | 32% | $1,329,382 |
| 2020 | 248 | 32 | 0% (0) | 32% | $1,948,892 |
| 2019 | 312 | 45 | None | 37% | $1,658,151 |
| 2018 | 308 | 47 | None | 37% | $695,860 |
| 2017 | 266 | 42 | 0% (0) | 32% | $554,851 |
| 2016 | 251 | 58 | 0% (0) | 20% | $291,578 |
| 2015 | 225 | 43 | None | 5% | $19,606 |
| 2014 | 167 | 49 | None | None | $10,294 |
| 2013 | 184 | 42 | None | 15% | $14,727 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Firdapse | None | 12 | $659,693 | $54,974 |
| Radicava Ors | None | 15 | $229,619 | $15,308 |
| Hizentra | Immune globulin | 33 | $220,198 | $6,673 |
| Gamunex-C | Immune globulin | 14 | $164,849 | $11,775 |
| Riluzole | None | 58 | $9,604 | $166 |
| Mycophenolate Mofetil | None | 20 | $1,410 | $70 |
| Duloxetine | None | 14 | $882 | $63 |
| Gabapentin | None | 25 | $825 | $33 |
| Pyridostigmine | None | 11 | $732 | $67 |
| Prednisone | None | 15 | $330 | $22 |
| Pregabalin | None | 13 | $283 | $22 |
2022: 8 drugs
| Firdapse | None | 12 | $611,332 | $50,944 |
| Octagam | Immune globulin | 13 | $392,595 | $30,200 |
| Gamunex-C | Immune globulin | 17 | $179,136 | $10,537 |
| Riluzole | None | 26 | $1,471 | $57 |
| Mycophenolate Mofetil | None | 29 | $1,461 | $50 |
| Azathioprine | None | 23 | $763 | $33 |
| Gabapentin | None | 38 | $586 | $15 |
| Prednisone | None | 38 | $304 | $8 |
2021: 7 drugs
| Firdapse | None | 15 | $737,277 | $49,152 |
| Octagam | Immune globulin | 12 | $371,957 | $30,996 |
| Gamunex-C | Immune globulin | 18 | $165,199 | $9,178 |
| Mycophenolate Mofetil | None | 21 | $1,901 | $91 |
| Riluzole | None | 29 | $1,723 | $59 |
| Gabapentin | None | 14 | $408 | $29 |
| Prednisone | None | 26 | $199 | $8 |
2020: 7 drugs
| Firdapse | None | 28 | $1,351,115 | $48,254 |
| Octagam | Immune globulin | 13 | $395,343 | $30,411 |
| Gamunex-C | Immune globulin | 16 | $125,864 | $7,866 |
| Mycophenolate Mofetil | None | 54 | $6,321 | $117 |
| Riluzole | None | 19 | $5,071 | $267 |
| Prednisone | None | 44 | $336 | $8 |
| Oxcarbazepine | None | 13 | $288 | $22 |
2019: 10 drugs
| Firdapse | None | 17 | $733,564 | $43,151 |
| Cuvitru | Immune globulin | 22 | $199,494 | $9,068 |
| Gamunex-C | Immune globulin | 15 | $140,128 | $9,342 |
| Hizentra | Immune globulin | 12 | $70,970 | $5,914 |
| Riluzole | None | 24 | $8,266 | $344 |
| Mycophenolate Mofetil | None | 39 | $5,057 | $130 |
| Pyridostigmine | None | 18 | $1,557 | $87 |
| Gabapentin | None | 18 | $437 | $24 |
| Duloxetine | None | 21 | $427 | $20 |
| Prednisone | None | 35 | $367 | $10 |
2018: 11 drugs
| Gammagard Liquid | Immune globulin | 15 | $271,993 | $18,133 |
| Gamunex-C | Immune globulin | 32 | $169,056 | $5,283 |
| Radicava | None | 14 | $143,775 | $10,270 |
| Riluzole | None | 37 | $7,773 | $210 |
| Lyrica | None | 13 | $7,228 | $556 |
| Mycophenolate Mofetil | None | 31 | $5,071 | $164 |
| Pyridostigmine | None | 15 | $1,216 | $81 |
| Oxcarbazepine | None | 18 | $553 | $31 |
| Gabapentin | None | 29 | $425 | $15 |
| Methotrexate | None | 11 | $381 | $35 |
| Prednisone | None | 27 | $169 | $6 |
2017: 10 drugs
| Gammagard Liquid | Immune globulin | 21 | $331,839 | $15,802 |
| Privigen | Immune globulin | 11 | $93,409 | $8,492 |
| Gamunex-C | Immune globulin | 15 | $58,648 | $3,910 |
| Riluzole | None | 16 | $5,616 | $351 |
| Pyridostigmine | None | 14 | $1,846 | $132 |
| Azathioprine | None | 13 | $1,084 | $83 |
| Gabapentin | None | 48 | $485 | $10 |
| Oxcarbazepine | None | 11 | $466 | $42 |
| Duloxetine | None | 16 | $396 | $25 |
| Prednisone | None | 25 | $304 | $12 |
2016: 6 drugs
| Riluzole | 18 | $3,211 | $178 |
| Pyridostigmine | 26 | $3,172 | $122 |
| Gabapentin | 42 | $833 | $20 |
| Oxcarbazepine | 16 | $666 | $42 |
| Methotrexate | 13 | $411 | $32 |
| Prednisone | 25 | $341 | $14 |
2015: 6 drugs
| Pyridostigmine | 31 | $3,550 | $115 |
| Duloxetine | 20 | $2,606 | $130 |
| Pramipexole Dihydrochloride | 12 | $1,158 | $96 |
| Oxcarbazepine | 26 | $744 | $29 |
| Gabapentin | 19 | $500 | $26 |
| Nortriptyline | 14 | $110 | $8 |
2014: 5 drugs
| Pyridostigmine | 29 | $1,169 | $40 |
| Prednisone | 21 | $362 | $17 |
| Levetiracetam | 11 | $273 | $25 |
| Gabapentin | 13 | $200 | $15 |
| Carbidopa-Levodopa | 11 | $152 | $14 |
2013: 6 drugs
| Mestinon | 11 | $1,655 | $150 |
| Pyridostigmine | 19 | $963 | $51 |
| Carbidopa-Levodopa | 24 | $565 | $24 |
| Divalproex Sodium Er | 12 | $478 | $40 |
| Levetiracetam | 13 | $305 | $23 |
| Prednisone | 14 | $109 | $8 |
Money from drug and device companies
$155 in 2025
| 2025 | 1 | 2 | None | $155 |
| 2023 | 1 | 3 | $2,063 | $2,068 |
| 2022 | 1 | 2 | $1,650 | $1,665 |
| 2021 | 1 | 1 | $3,163 | $3,163 |
| 2019 | 1 | 1 | None | $123 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ucb | Zilbrysq | $155 | 2 payments
|
See all 2 published payments
| Ucb | Education · 2025-12-12 | Zilbrysq | $18 |
| Ucb | Meals · 2025-10-29 | None | $138 |
See earlier years (2023, 2022, 2021, 2019)
2023: $2,068
| Ucb | Neupro | $2,068 | 3 payments
|
2022: $1,665
| Ucb | None | $1,665 | 2 payments
|
2021: $3,163
| Ucb | None | $3,163 | 1 payment
|
2019: $123
| Akcea Therapeutics | Tegsedi | $123 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Janssen Research & Development, LLC · Phase 3 Multi Center Randomized Double Blind Placebo Controlled Study To Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered To Adults With Generalized Myasthenia Gravis · 2021 | Their institution | $25,467 |
| Janssen Research & Development, LLC · An Open Label Extension Study of Momm281004 To Evaluate the Safety Tolerability and Efficacy of M281 Administered To Patients With Generalized Myasthenia Gravis · 2021 | Their institution | $15,403 |
| Janssen Research & Development, LLC · Phase 3 Multi Center Randomized Double Blind Placebo Controlled Study To Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered To Adults With Generalized Myasthenia Gravis · 2023 | Their institution | $13,021 |
| Janssen Research & Development, LLC · An Open-Label Extension Study of Mom-M281-004 To Evaluate the Safety, Tolerability, and Efficacy of M281 Administered To Patients With Generalized Myasthenia Gravis · 2020 | Their institution | $5,119 |
| Janssen Research & Development, LLC · A Study To Evaluate the Safety Tolerability Efficacy Pharmacokinetics and Pharmacodynamics of M281 Administered To Adults With Generalized Myasthenia Gravis · 2022 | Their institution | $4,364 |
| Janssen Research & Development, LLC · A Study To Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered To Adults With Generalized Myasthenia Gravis · 2020 | Their institution | $3,785 |
| CATALYST PHARMACEUTICALS, INC. · An Open-Label, Expanded Access Protocol for Amifampridine Phosphate Treatment in Patients With Congenital Myasthenia Syndrome (Cms), Lambert Eaton Myasthenia Syndrome (Lems), and Downbeat Nystagmus · 2019 | Their institution | $2,540 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1891821401
- Licence
- CA G53824California G53824: Current · expires 2028-08-31
- Trained
- Yale University School of Medicine, 1982
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G538240
- Taxonomy
- Federal specialty code 2084N0008X (2084N0008X); Neurology (2084N0400X); Federal specialty code 2084N0600X (2084N0600X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-26
- NPI last updated
- 2023-11-06
- NPI record certified
- 2023-11-06
This is when the NPI record was last certified, not a medical board exam.